Tharimmune, Inc. announced on May 19, 2025, the appointment of James Gordon Liddy (CDR US Navy SEAL (Ret)) as a Key Strategic Advisor. Mr. Liddy is a renowned counter-terrorism and critical infrastructure expert.
His appointment is specifically aimed at supporting the company's program against weaponized fentanyl and other high-potency opioids. This follows positive FDA feedback on the New Drug Application (NDA) path for TH104 in this indication.
Mr. Liddy's expertise is expected to provide invaluable guidance as Tharimmune advances TH104 as a critical medical countermeasure. This strategic addition reinforces the company's commitment to addressing national security needs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.